Methods of using antibodies to determine periostin levels in a sample

Patent metadata

Field	Value
Publication number	US-10775388-B2
Application number	US-201515106223-A
Country	US
Kind code	B2
Filing date	Feb 5, 2015
Priority date	Feb 7, 2014
Publication date	Sep 15, 2020
Grant date	Sep 15, 2020

Abstract

This disclosure provides a robust, sensitive, and specific assay for the detection and measurement of periostin levels in samples obtained from human patients having, or suspected of having an IL-13-mediated disease or disorder. The disclosure further provides novel antiperiostin monoclonal antibodies that recognize at least isoforms 1, 2, 3, 4, 7, and 8 of human periostin, and assay kits comprising one or more of these antibodies.

First claim

What is claimed is:

1. A method of measuring periostin levels in a sample obtained from a subject comprising assaying the sample in an immunoassay employing an isolated antibody or antigen-binding fragment thereof which binds to the same periostin epitope as monoclonal antibody 4B4.B11 produced from a hybridoma deposited at the American Type Culture Collection (ATCC) under Deposit No. PTA-120210 and an isolated antibody or antigen-binding fragment thereof which binds to the same periostin epitope as monoclonal antibody 7B5.C4 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120211.

2. The method of claim 1 , wherein each of the isolated antibodies or antigen-binding fragments thereof competitively inhibits binding of monoclonal antibody 4B4.B11 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120210 and monoclonal antibody 7B5.C4 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120211 to periostin.

3. The method of claim 1 , wherein the isolated antibody or antigen-binding fragment thereof which binds to the same periostin epitope as monoclonal antibody 4B4.B11 comprises three heavy chain variable domain (VH) complementarity determining regions (CDRs) VHCDR1, VHCDR2 and VHCDR3, and three light chain variable domain (VL) CDRs VLCDR1, VLCDR2, and VLCDR3 identical to the CDRs of monoclonal antibody 4B4.B11 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120210, and the isolated antibody or antigen-binding fragment thereof which binds to the same periostin epitope as monoclonal antibody 7B5.C4 comprises three VH CDRs VHCDR1, VHCDR2 and VHCDR3 and three VL CDRs VLCDR1, VLCDR2, and VLCDR3 identical to the CDRs of monoclonal antibody 7B5.C4 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120211.

4. The method of claim 1 , which employs an isolated antibody or antigen-binding fragment thereof comprising a VH and a VL identical to the VH and VL of monoclonal antibody 4B4.B11 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120210, and an isolated antibody or antigen binding fragment thereof comprising a VH and VL identical to the VH and VL of monoclonal antibody 7B5.C4 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120211.

5. The method of claim 1 , wherein the antibody or fragment thereof further comprises a heterologous polypeptide fused thereto selected from a stabilizing polypeptide, a tag, a label, and a combination thereof.

6. The method of claim 1 , wherein the antibody or fragment thereof is conjugated to a heterologous moiety comprising one or more of a peptide, a protein, an enzyme, a lipid, a heterologous antibody or fragment thereof, a detectable label, or polyethylene glycol (PEG).

7. The method of claim 6 , wherein the heterologous moiety comprises biotin, ruthenium chelate, or acridinium.

8. The method of claim 1 , wherein the sample taken from the patient comprises one or more of whole blood, serum, plasma, saliva, sputum, bronchoalveolar lavage fluid, lung epithelial cells, or nasal polyps.

9. The method of claim 8 , wherein one or more control samples are obtained from normal healthy individuals; patients with a non-IL-13-mediated subset of asthma, COPD, IPF, atopic dermatitis, or UC; a pre-determined standard amount of isolated periostin; or a combination thereof.

10. The method of claim 9 , wherein the one or more samples obtained from normal healthy individuals or patients with a non-IL-13-mediated subset of asthma, COPD, IPF, atopic dermatitis, or UC comprise one or more of whole blood, serum, plasma, saliva, sputum, bronchoalveolar lavage fluid, lung epithelial cells, or a combination thereof, wherein the control sample is matched to the sample taken from the patient.

11. The method of claim 1 , wherein the immunoassay comprises a sandwich immunoassay comprising a first “capture” antibody or antigen-binding fragment thereof attached to a solid support, and a second “detection” antibody or antigen binding fragment thereof.

12. The method of claim 11 , wherein the capture antibody is 4B4.B11 and the detection antibody is 7B5.C4.

13. The method of claim 11 , wherein the immunoassay comprises:
(a) attaching a capture antibody or antigen-binding fragment thereof to a solid support;
(b) applying the patient sample or control sample under conditions sufficient to allow periostin, if present in the sample, to bind to the capture antibody or antigen-binding fragment thereof;
(c) applying the detection antibody or antigen-binding fragment thereof under conditions sufficient to allow binding to periostin already bound to the capture antibody or antigen-binding fragment thereof; and
(d) measuring the amount of detection antibody or antigen-binding fragment thereof bound to periostin.

14. The method of claim 13 , wherein the detection antibody or fragment thereof further comprises a detectable label, wherein the detectable label is biotin, ruthenium chelate, or acridinium.

15. The method of claim 11 , wherein the capture antibody is 4B4.B11 or 7B5.C4.

16. The method of claim 11 , wherein the detection antibody is 4B4.B11 or 7B5.C4.

17. The method of claim 11 , wherein the capture antibody is 7B5.C4 and the detection antibody is 4B4.B11.

18. A method for determining periostin levels in a test sample, the method comprising:
(a) contacting the test sample with at least one capture antibody, wherein the capture antibody binds to an epitope on periostin or a fragment of periostin to form a capture antibody-periostin antigen complex;
(b) contacting the capture antibody-periostin antigen complex with at least one detection antibody comprising a detectable label, wherein the detection antibody binds to an epitope on periostin that is not bound by the capture antibody and forms a capture antibody-periostin antigen-detection antibody complex; and
(c) determining the periostin concentration in the test sample based on the signal generated by the detectable label in the capture antibody-periostin antigen-detection antibody complex formed in (b),
wherein the at least one capture antibody and the at least one detection antibody comprises an isolated antibody or antigen-binding fragment thereof which comprises:
(i) a heavy chain variable domain (VH) with three heavy chain complementarity determining regions (CDRs) VHCDR1, VHCDR2 and VHCDR3, and a light chain variable domain (VL) with three light chain CDRs VLCDR1, VLCDR2, and VLCDR3, wherein the CDRs of the isolated antibody or fragment thereof are identical to the CDRs of monoclonal antibody 4B4.B11 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120210 or monoclonal antibody 7B5.C4 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120211;
(ii) a VH and a VL identical to the VH and VL of monoclonal antibody 4B4.B11 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120210 or monoclonal antibody 7B5.C4 produced from a hybridoma deposited at the ATCC under Deposit No. PTA-120211; or
(iii) monoclonal antibody 4B4.B11 produced by the hybridoma deposited at the ATCC under Deposit No. PTA-120210 or monoclonal antibody 7B5.C4 produced by the hybridoma deposited at the ATCC under Deposit No. PTA-120211, and

wherein the least one capture antibody is different from the at least one detection antibody.

19. The method of claim 18 , further comprising comparing the signal generated by the detectable label as a direct or indirect indication of the periostin concentration in the test sample to a signal gener

Assignees

• Medimmune Llc
• Abbott Lab

Inventors

• Chowdhury Partha S
• Varkey Reena
• Liang Meina
• Lee Yen-Wah
• Streicher Katie
• Ranade Koustubh
• Grant Ethan
• Greenlees Lydia
• Yao Yihong
• Parker Melissa
• Davis Gerard
• Jeanblanc Nicolette
• Brophy Susan
• Dille Bruce

Classifications

• G01N33/6869 Primary

  Interleukin · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title

• A61K31/56

  Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids · CPC title

• G01N2800/202

  Dermatitis · CPC title

• A61P17/00

  Drugs for dermatological disorders · CPC title